ArticleFrontiers in medicine2026
Adjunctive topical mesenchymal stem cell-derived secretome-enriched biological dressings in pediatric complex wounds: a retrospective case series.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Mesenchymal stem cell (MSC)-derived secretome, including extracellular vesicles (EVs), has emerged as a potential cell-free regenerative approach due to its immunomodulatory and tissue repair-associated properties. While topical applications have been explored in adult dermatologic settings, clinical evidence in pediatric patients with complex cutaneous wounds remains scarce. Methods: A retrospective observational case series was conducted at a tertiary referral pediatric hospital. Medical records and photographic documentation of six pediatric patients with complex cutaneous wounds treated with topical biological dressings containing MSC-derived secretome enriched in EVs were reviewed between January 2020 and January 2024. All patients received standard-of-care management in addition to adjunctive application of the biological dressings. Clinical evolution and treatment tolerability were assessed descriptively. Results: Progressive re-epithelialization and clinical improvement were observed across all cases based on clinical and photographic assessment. Time to complete re-epithelialization ranged from 6 to 14 days across heterogeneous wound etiologies. Estimated wound reduction ranged from approximately 85 to >90% at defined time points. No treatment-related adverse events were documented during follow-up. Conclusion: In this retrospective case series, progressive re-epithelialization was documented during follow-up in pediatric patients with complex cutaneous wounds receiving adjunctive topical MSC-derived secretome-enriched biological dressings alongside standard care. However, given the observational design, small sample size, heterogeneous diagnoses, and absence of a control group, these findings should be interpreted as descriptive and hypothesis-generating. Prospective, controlled studies are needed to better define the therapeutic role and safety profile of these interventions in pediatric regenerative dermatology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.